Real-world discontinuation rates of ocrelizumab are low, similar to pivotal trials, with rates between 3.2% and 4.1% for RRMS and PPMS. Side effects are the most common reason for discontinuation ...

who previously worked to develop Ocrevus (ocrelizumab) for both relapsing-remitting and primary-progressive MS while at Roche. In 2019, a team led by Find advisor Dominique Bagnard, who is a ...

That's because the primary progressive symptoms tend to be caused by neurons in the CNS physically breaking down, as opposed ...

Ocrevus, also known by its generic name ocrelizumab ... of multiple sclerosis (MS): relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).

Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...